Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20047554 | 0.91 | GAA (0.38) | CA2ALDH1A1MAPTGAAKMT2A | |
| SCHEMBL20047580 | 0.91 | GAA (0.38) | CA2ALDH1A1MAPTGAAKMT2A | |
| SCHEMBL20043228 | 0.87 | CA2 (0.36) | CA2GABRA1GABRB2ALDH1A1ACHE | |
| SCHEMBL20043226 | 0.87 | CA2 (0.36) | CA2GABRA1GABRB2ALDH1A1ACHE | |
| SCHEMBL20047454 | 0.84 | NQO2 (0.39) | CA2ALDH1A1MAPTNQO2TP53 | |
| SCHEMBL20047536 | 0.84 | NQO2 (0.39) | CA2ALDH1A1MAPTNQO2TP53 | |
| SCHEMBL25101360 | 0.82 | NQO2 (0.50) | CA2ALDH1A1ACHETSHRTDP1 | |
| SCHEMBL20043221 | 0.81 | CA2 (0.32) | CA2 | |
| SCHEMBL20043232 | 0.80 | ATM (0.36) | CA2TSHRMAPTKMT2AATM | |
| SCHEMBL20043224 | 0.80 | LCK (0.33) | CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919914-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919914-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | CA2 2157/4885GABRA1 3361/4885GABRB2 3160/4885 |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CA2 2157/4885GABRA1 3361/4885GABRB2 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.